Sandra Levy
ARTICLES BY THIS AUTHOR
- 10/3/2019
FDA approves new indication for AbbVie’s Mavyret
Mavyret is now the first eight-week treatment approved for all treatment-naïve adult and certain pediatric patients with HCV genotypes 1-6 both without cirrhosis and with compensated cirrhosis. - 10/3/2019
Superstars: Pharmacists who went beyond the call of duty
DSN found some of the many pharmacists who do more than asked. Here are their stories. - 10/3/2019
Alembic launches generic Optivar
Alembic's azelastine ophthalmic solution 0.05% is provided as 6mL in a sterile dispensing bottle. - 10/3/2019
Albertsons to switch to recycled prescription bags
Albertsons’ move to recycled prescription bags will save more than 5,000 trees each year, the company said. - 10/3/2019
AmerisourceBergen selected by Karyopharm to support Xpovio
AmerisourceBergen has been chosen by Karyopharm to introduce a new treatment for patients with relapsed or refractory multiple myeloma. - 10/3/2019
NACDS 21st annual Foundation Dinner to feature entertainer Jim Gaffigan
Grammy award-nominated entertainer Jim Gaffigan will headline NACDS Foundation dinner, which is dedicated to improving patient outcomes and public health. - 10/2/2019
MedicaSafe partners with Amneal on generic Suboxone monitoring
MedicaSafe will combine Amneal's generic of Suboxone (buprenorphine and naloxone) with its smart medication systems to treat opioid dependence. - 10/2/2019
Diplomat taps David Skomo as CastiaRx COO
Following the retirement of Chris Luthin, David Skomo has been named COO of Diplomat's pharmacy benefit manager CastiaRx. - 10/2/2019
Perrigo relaunches generic Transderm Scop
Transderm Scop and generics had a market value of roughly $147 million for the 12 months ending August 2019. - 10/2/2019
Hy-Vee suspends sale of Zantac and Topcare brand ranitidine products
Hy-Vee has temporarily stopped selling OTC Zantac and Topcare brand ranitidine products, following an FDA alert that these products contain a probable human carcinogen.
